Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PF-00232798 · 1 trial · 1 indication
Viral load was determined using the Roche COBAS Taqman HIV-1 assay with a lower limit of detection of 40 copies per milliliter (copies/mL). Samples with an initial reading of less than 1,000,000 copies/mL were diluted into range and re-assayed.
| Arm | Type | Description |
|---|---|---|
| PF-00232798 40 mg | ACTIVE_COMPARATOR | - |
| PF-00232798 300 mg | ACTIVE_COMPARATOR | - |
| PF-00232798 400 mg | ACTIVE_COMPARATOR | - |
| PF-00232798 5 mg | ACTIVE_COMPARATOR | - |
| PF-00232798 20 mg | ACTIVE_COMPARATOR | - |
| PF-00232798 150 mg | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| PF-00232798 | DRUG | Solution, 20 mg. once daily, 10 days |
Inclusion Criteria: * Asymptomatic HIV-1 infected male patients between the ages of 18 and 55 years inclusive. * Patients with CCR5 tropic virus as determined by the Monogram PhenoSense Entry assay. Exclusion Criteria: * Patients who have received any experimental drug within the past four months...
PF-00232798 is an investigational small molecule drug that Pfizer developed for the treatment of HIV. It was studied as a Phase 2 candidate in HIV positive patients. It is not an approved medicine and no longer appears to be in active clinical development.
PF-00232798 was studied for the treatment of HIV infection. Its only recorded clinical trial enrolled HIV positive adult patients in Germany. The drug is investigational and has not been approved for any use.
PF-00232798 was developed by Pfizer, Inc., which trades on the New York Stock Exchange under the ticker PFE. Pfizer sponsored the Phase 2 HIV study of the compound.
PF-00232798 reached Phase 2 clinical development for HIV. That Phase 2 trial has been completed, and the drug is not currently listed as being in an active trial. It is an investigational agent and is not FDA approved.
PF-00232798 was evaluated in one clinical trial, NCT00495677, titled A Phase 2 Study Of PF-00232798 In HIV Positive Patients. The completed study enrolled 43 participants in Germany and used a randomized, double-blind, active-controlled design.